Who / What
Galapagos NV is a Belgian pharmaceutical research company focused on developing novel medicines. The company specializes in creating treatments for autoimmune diseases, inflammatory conditions, and cystic fibrosis.
Background & History
Galapagos NV was founded in 1999 as Galapagos Genomics and is headquartered in Mechelen, Belgium. It has expanded its operations with additional locations across Europe and in Boston. The company has built a pipeline of drug candidates targeting specific disease mechanisms.
Why Notable
Galapagos plays a significant role in pharmaceutical research, particularly in autoimmune and inflammatory diseases like rheumatoid arthritis and Crohn's disease. The company has developed specialized drugs that address unmet medical needs in these areas. Its research contributes to advancing treatment options for chronic conditions affecting millions worldwide.
In the News
Galapagos remains relevant as it continues its clinical development programs for conditions like ulcerative colitis and psoriasis. Recent research advancements keep the company at the forefront of inflammatory disease treatment development. Their ongoing work addresses significant healthcare challenges in autoimmune disorders.
